Novo Nordisk A/S (NVO)
45.75
-0.01
(-0.02%)
USD |
NYSE |
May 07, 16:00
45.50
-0.25
(-0.55%)
Pre-Market: 04:09
Novo Nordisk Research and Development Expense (Annual) : 6.838B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Evaxion AS | 9.691M |
| Ascendis Pharma A/S | 333.10M |
| Prothena Corp. Plc | 134.85M |
| Viking Therapeutics, Inc. | 344.96M |
| Cellectis SA | 75.08M |